Vaxart Inc.

Vaxart Inc. is a biotechnology company focused on the development of oral recombinant vaccines administered by tablet rather than injection. This innovative approach aims to address vaccine distribution and compliance challenges by offering a painless, cold-chain independent, and potentially more cost-effective alternative to traditional vaccine delivery methods. Vaxart's pipeline targets both viral and bacterial pathogens, emphasizing diseases such as COVID-19, influenza, and norovirus, which have significant public health implications across various demographics. The company operates within the broader biotechnology and pharmaceutical sectors, contributing to advancements in preventive healthcare and infectious disease management. Headquartered in South San Francisco, Vaxart plays a pivotal role in research and development, leveraging its proprietary VAAST™ platform to produce vaccines that are not only effective but also align with the complexities of modern-day distribution logistics. This approach allows Vaxart to contribute meaningfully to the global effort to increase vaccine accessibility and coverage, especially in resource-constrained environments. As part of the competitive landscape of biotechnology firms, Vaxart's innovations are integral to the sector's evolution toward more user-friendly and accessible healthcare solutions.